Silence Therapeutics (SLN) Assets Average (2025 - 2026)
Silence Therapeutics (SLN) posted Assets Average of $123.3 million for Q1 2026, down 11.38% sequentially from $139.1 million in Q4 2025, and down 36.44% YoY from $194.0 million in Q1 2025.
Silence Therapeutics (SLN) Assets Average (2025 - 2026) Analysis & Trends
Silence Therapeutics has reported Assets Average for 2 years, with the latest figure at $123.3 million in Q1 2026.
- Quarterly Assets Average fell 36.44% year-over-year to $123.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.3 million (down 36.44% YoY) and the FY2025 annual result came in at $167.0 million, up 3.72% from the prior year.
- Assets Average slipped to $123.3 million in Q1 2026 per SLN's latest filing, from $139.1 million in the prior quarter.
- Over five years, Assets Average peaked at $194.0 million in Q1 2025 and troughed at $123.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 110.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.77 Mn |
| Mar 31, 2026 | 123.28 Mn |
| Dec 31, 2025 | 139.12 Mn |
| Sep 30, 2025 | 156.01 Mn |
| Jun 30, 2025 | 175.27 Mn |
| Mar 31, 2025 | 193.97 Mn |